Blisibimod, an investigational anti-BAFF molecule in Phase III trails for the treatment of systemic lupus erythematosus and Phase II trials for the treatment of IgA nephropathy.
Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus.
These metabolically active B cells proliferate in the germinal center of a secondary lymphoid follicle following exposure to follicular dendritic cell cytokines, such as IL-6, IL-15, 8D6, and BAFF.
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.
TACI was later found to play a crucial role in humoral immunity by interacting with two members of the TNF family: BAFF and APRIL.
B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population.
The O'Reilly Factor | The X Factor (UK) | Microphthalmia-associated transcription factor | The X Factor | Cell nucleus | Fear Factor | Soft Cell | Max Factor | Cell biology | Cell | cell | cell (biology) | The X Factor (TV series) | B-cell activating factor | Epidermal growth factor receptor | Cell (journal) | Cell (biology) | T cell | cell membrane | Psi Factor: Chronicles of the Paranormal | Mesenchymal stem cell | Cell membrane | Astro Boy: Omega Factor | Hematopoietic stem cell transplantation | cell culture | Cell Biology | twist transcription factor | The X Factor (U.S.) | The X Factor (UK TV series) | The X Factor (UK series 2) |